R1 RCM Inc. (NASDAQ:RCM) Stake Reduced by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. cut its stake in R1 RCM Inc. (NASDAQ:RCM) by 49.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,254 shares of the healthcare provider’s stock after selling 12,000 shares during the period. Crossmark Global Holdings Inc.’s holdings in R1 RCM were worth $174,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Values First Advisors Inc. acquired a new position in shares of R1 RCM during the third quarter worth approximately $88,000. Allspring Global Investments Holdings LLC grew its stake in shares of R1 RCM by 589.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider’s stock worth $44,000 after purchasing an additional 2,669 shares in the last quarter. Creative Planning bought a new stake in shares of R1 RCM during the third quarter valued at about $142,000. GAMMA Investing LLC lifted its holdings in R1 RCM by 41.3% in the third quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock worth $37,000 after purchasing an additional 759 shares during the period. Finally, Bardin Hill Management Partners LP lifted its holdings in R1 RCM by 98.7% in the second quarter. Bardin Hill Management Partners LP now owns 525,211 shares of the healthcare provider’s stock worth $6,597,000 after purchasing an additional 260,891 shares during the period. 61.10% of the stock is currently owned by institutional investors.

R1 RCM Trading Up 0.1 %

R1 RCM stock opened at $14.31 on Tuesday. R1 RCM Inc. has a 52 week low of $8.87 and a 52 week high of $15.12. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.79 and a current ratio of 1.79. The firm has a market capitalization of $6.04 billion, a price-to-earnings ratio of -95.39 and a beta of 0.84. The company has a 50 day moving average price of $14.22 and a 200 day moving average price of $13.42.

R1 RCM (NASDAQ:RCM) last issued its earnings results on Tuesday, November 5th. The healthcare provider reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The business had revenue of $656.80 million during the quarter, compared to analyst estimates of $640.93 million. R1 RCM had a negative return on equity of 2.18% and a negative net margin of 2.48%. The firm’s revenue was up 14.7% compared to the same quarter last year. Research analysts forecast that R1 RCM Inc. will post -0.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on RCM shares. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price target on shares of R1 RCM in a research report on Monday, July 22nd. TD Cowen restated a “hold” rating and issued a $14.30 target price (down from $20.00) on shares of R1 RCM in a research report on Monday, August 5th. Jefferies Financial Group cut R1 RCM from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $14.30 price objective on shares of R1 RCM in a report on Friday, October 4th. Finally, Stephens lowered R1 RCM from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st. Thirteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $15.41.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.